Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic
effect of a single oral dose of BAY63-2521 in patients with pulmonary hypertension due to
chronic obstructive pulmonary disease (COPD).